Academic Journal
Live Attenuated Zoster Vaccine Boosts Varicella Zoster Virus (VZV)-Specific Humoral Responses Systemically and at the Cervicovaginal Mucosa of Kenyan VZV-Seropositive Women.
| Title: | Live Attenuated Zoster Vaccine Boosts Varicella Zoster Virus (VZV)-Specific Humoral Responses Systemically and at the Cervicovaginal Mucosa of Kenyan VZV-Seropositive Women. |
|---|---|
| Authors: | Perciani CT; Department of Immunology, University of Toronto, Ontario, Canada., Sekhon M; Department of Immunology, University of Toronto, Ontario, Canada., Hundal S; Department of Immunology, University of Toronto, Ontario, Canada., Farah B; Kenyan AIDS Vaccine Initiative-Institute of Clinical Research, Nairobi, Kenya., Ostrowski MA; Department of Immunology, University of Toronto, Ontario, Canada.; Keenan Research Centre for Biomedical Science of St Michael's Hospital, Toronto, Ontario, Canada., Anzala AO; Kenyan AIDS Vaccine Initiative-Institute of Clinical Research, Nairobi, Kenya.; Department of Medical Microbiology, University of Nairobi, Kenya., McKinnon LR; Department of Medical Microbiology, University of Nairobi, Kenya.; Department of Medical Microbiology and Infectious Diseases, Rady College of Medicine, University of Manitoba, Winnipeg, Canada.; Centre for the AIDS Programme of Research in South Africa, Durban., Jaoko W; Kenyan AIDS Vaccine Initiative-Institute of Clinical Research, Nairobi, Kenya.; Department of Medical Microbiology, University of Nairobi, Kenya., MacDonald KS; Department of Immunology, University of Toronto, Ontario, Canada.; Section of Infectious Diseases, Department of Internal Medicine, Rady College of Medicine, University of Manitoba, Winnipeg, Canada. |
| Corporate Authors: | Institute of Tropical and Infectious Diseases (UNITID) Group and the Kenyan AIDS Vaccine Initiative–Institute of Clinical Research (KAVI-ICR) Team |
| Source: | The Journal of infectious diseases [J Infect Dis] 2018 Sep 08; Vol. 218 (8), pp. 1210-1218. |
| Publication Type: | Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't |
| Language: | English |
| Journal Info: | Publisher: Oxford University Press Country of Publication: United States NLM ID: 0413675 Publication Model: Print Cited Medium: Internet ISSN: 1537-6613 (Electronic) Linking ISSN: 00221899 NLM ISO Abbreviation: J Infect Dis Subsets: MEDLINE |
| Imprint Name(s): | Publication: Jan. 2011- : Oxford : Oxford University Press Original Publication: 1904-2010 : Chicago, IL : University of Chicago Press |
| MeSH Terms: | Immunity, Humoral*, Antibodies, Viral/*metabolism , Herpesvirus 3, Human/*isolation & purification , Mucous Membrane/*immunology , Vagina/*immunology , Varicella Zoster Virus Infection/*prevention & control, Antibodies, Viral/blood ; Herpes Zoster Vaccine/immunology ; Kenya/epidemiology ; Varicella Zoster Virus Infection/epidemiology ; Varicella Zoster Virus Infection/immunology ; Female ; Humans ; Vaccines, Attenuated |
| Abstract: | Background: Attenuated varicella zoster virus (VZV) is a promising vector for recombinant vaccines. Because human immunodeficiencyvirus (HIV) vaccines are believed to require mucosal immunogenicity, we characterized mucosal VZV-specific humoral immunity following VZVOka vaccination. Methods: Adult Kenyan VZV-seropositive women (n = 44) received a single dose of the live zoster VZVOka vaccine. The anamnestic responses to the virus were followed longitudinally in both plasma and mucosal secretions using an in-house glycoprotein enzyme-linked immunosorbent assay and safety and reactogenicity monitored. VZV seroprevalence and baseline responses to the virus were also characterized in our cohorts (n = 288). Results: Besides boosting anti-VZV antibody responses systemically, vaccination also boosted anti-VZV immunity in the cervicovaginal mucosa with a 2.9-fold rise in immunoglobulin G (P < .0001) and 1.6-fold rise in immunoglobulin A (IgA) (P = .004) from the time before immunization and 4 weeks postvaccination. Baseline analysis demonstrated high avidity antibodies at the gastrointestinal and genital mucosa of VZV-seropositive women. Measurement of VZV-specific IgA in saliva is a sensitive tool for detecting prior VZV infection. Conclusions: VZVOka vaccine was safe and immunogenic in VZV-seropositive adult Kenyan women. We provided compelling evidence of VZV ability to induce genital mucosa immunity. Clinical Trials Registration: NCT02514018. |
| References: | J Infect Dis. 2008 Mar 1;197 Suppl 2:S61-5. (PMID: 18419411) Vaccine. 2006 Nov 17;24(47-48):6875-85. (PMID: 17050042) BMJ Open. 2016 Apr 20;6(4):e010213. (PMID: 27098823) Pediatr Infect Dis J. 2002 Apr;21(4):337-42. (PMID: 12075766) J Infect Dis. 1998 Nov;178 Suppl 1:S52-4. (PMID: 9852974) Mucosal Immunol. 2018 Mar;11(2):512-522. (PMID: 28792003) J Clin Virol. 2009 Jan;44(1):9-14. (PMID: 18823815) Clin Diagn Lab Immunol. 1996 May;3(3):365-7. (PMID: 8705687) Curr Top Microbiol Immunol. 2010;342:189-209. (PMID: 20397071) J Infect Dis. 2011 Oct 1;204(7):1075-85. (PMID: 21881123) BMJ Open. 2017 Sep 21;7(9):e017391. (PMID: 28939581) J Infect Dis. 2008 Mar 15;197(6):825-35. (PMID: 18419349) N Engl J Med. 2005 Jun 2;352(22):2271-84. (PMID: 15930418) J Infect Dis. 2014 Nov 15;210(10):1573-81. (PMID: 24823623) J Clin Invest. 2014 Jul;124(7):3147-58. (PMID: 24911151) Adv Virol. 2013;2013:219439. (PMID: 23843791) J Immunol. 2014 Sep 15;193(6):3126-33. (PMID: 25143442) Lancet. 1974 Nov 30;2(7892):1288-90. (PMID: 4139526) J Infect Dis. 1996 Nov;174 Suppl 3:S314-9. (PMID: 8896538) PLoS Pathog. 2016 Dec 13;12(12):e1006104. (PMID: 27959961) Trends Immunol. 2014 Nov;35(11):526-37. (PMID: 25113637) J Med Virol. 2012 Dec;84(12):2018-25. (PMID: 23080511) JAMA. 2005 Aug 17;294(7):797-802. (PMID: 16106004) N Engl J Med. 2015 May 28;372(22):2087-96. (PMID: 25916341) J Clin Lab Anal. 2007;21(3):201-6. (PMID: 17506479) J Am Osteopath Assoc. 2009 Jun;109(6 Suppl 2):S13-7. (PMID: 19553630) J Infect Dis. 2011 Feb 1;203(3):312-5. (PMID: 21208922) J Immunol. 2014 Sep 15;193(6):3113-25. (PMID: 25135832) N Engl J Med. 2005 Feb 3;352(5):450-8. (PMID: 15689583) |
| Grant Information: | THA-11960 Canada CIHR |
| Contributed Indexing: | Investigator: J Kimano; J Oyugi; E Irungu; J Nyakio; R Malogo; R Mahira; G Mutua; L Atambo; B Nyaoke; J Nyange; J Omungo; T Kotikot; MW Gichuho; H Ogutu; R Ndambuki; E Museve; HN Gakure; D Essendi; E Mutiska; B Onsembe; M Akiso; S Ogola; N Wanjiku; R Langat; J Indangasi; N Mwakisha; I Mwangi; M Agwaya; R Chirchir; R Alila; L Said; J Wakonyo; M Musanga; C Kamau; M Muriuki; J Ndalamia; C Ngeli; L Lusik |
| Molecular Sequence: | ClinicalTrials.gov NCT02514018 |
| Substance Nomenclature: | 0 (Antibodies, Viral) 0 (Herpes Zoster Vaccine) 0 (Vaccines, Attenuated) |
| Entry Date(s): | Date Created: 20180526 Date Completed: 20190916 Latest Revision: 20190916 |
| Update Code: | 20260130 |
| PubMed Central ID: | PMC6129112 |
| DOI: | 10.1093/infdis/jiy320 |
| PMID: | 29800309 |
| Database: | MEDLINE |
| FullText | Text: Availability: 0 CustomLinks: – Url: https://resolver.ebsco.com/c/fiv2js/result?sid=EBSCO:cmedm&genre=article&issn=15376613&ISBN=&volume=218&issue=8&date=20180908&spage=1210&pages=1210-1218&title=The Journal of infectious diseases&atitle=Live%20Attenuated%20Zoster%20Vaccine%20Boosts%20Varicella%20Zoster%20Virus%20%28VZV%29-Specific%20Humoral%20Responses%20Systemically%20and%20at%20the%20Cervicovaginal%20Mucosa%20of%20Kenyan%20VZV-Seropositive%20Women.&aulast=Perciani%20CT&id=DOI:10.1093/infdis/jiy320 Name: Full Text Finder (for New FTF UI) (ns324271) Category: fullText Text: Full Text Finder MouseOverText: Full Text Finder |
|---|---|
| Header | DbId: cmedm DbLabel: MEDLINE An: 29800309 AccessLevel: 3 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: Live Attenuated Zoster Vaccine Boosts Varicella Zoster Virus (VZV)-Specific Humoral Responses Systemically and at the Cervicovaginal Mucosa of Kenyan VZV-Seropositive Women. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AU" term="%22Perciani+CT%22">Perciani CT</searchLink>; Department of Immunology, University of Toronto, Ontario, Canada.<br /><searchLink fieldCode="AU" term="%22Sekhon+M%22">Sekhon M</searchLink>; Department of Immunology, University of Toronto, Ontario, Canada.<br /><searchLink fieldCode="AU" term="%22Hundal+S%22">Hundal S</searchLink>; Department of Immunology, University of Toronto, Ontario, Canada.<br /><searchLink fieldCode="AU" term="%22Farah+B%22">Farah B</searchLink>; Kenyan AIDS Vaccine Initiative-Institute of Clinical Research, Nairobi, Kenya.<br /><searchLink fieldCode="AU" term="%22Ostrowski+MA%22">Ostrowski MA</searchLink>; Department of Immunology, University of Toronto, Ontario, Canada.; Keenan Research Centre for Biomedical Science of St Michael's Hospital, Toronto, Ontario, Canada.<br /><searchLink fieldCode="AU" term="%22Anzala+AO%22">Anzala AO</searchLink>; Kenyan AIDS Vaccine Initiative-Institute of Clinical Research, Nairobi, Kenya.; Department of Medical Microbiology, University of Nairobi, Kenya.<br /><searchLink fieldCode="AU" term="%22McKinnon+LR%22">McKinnon LR</searchLink>; Department of Medical Microbiology, University of Nairobi, Kenya.; Department of Medical Microbiology and Infectious Diseases, Rady College of Medicine, University of Manitoba, Winnipeg, Canada.; Centre for the AIDS Programme of Research in South Africa, Durban.<br /><searchLink fieldCode="AU" term="%22Jaoko+W%22">Jaoko W</searchLink>; Kenyan AIDS Vaccine Initiative-Institute of Clinical Research, Nairobi, Kenya.; Department of Medical Microbiology, University of Nairobi, Kenya.<br /><searchLink fieldCode="AU" term="%22MacDonald+KS%22">MacDonald KS</searchLink>; Department of Immunology, University of Toronto, Ontario, Canada.; Section of Infectious Diseases, Department of Internal Medicine, Rady College of Medicine, University of Manitoba, Winnipeg, Canada. – Name: AuthorCorporate Label: Corporate Authors Group: Au Data: <searchLink fieldCode="CA" term="%22Institute+of+Tropical+and+Infectious+Diseases+%28UNITID%29+Group+and+the+Kenyan+AIDS+Vaccine+Initiative–Institute+of+Clinical+Research+%28KAVI-ICR%29+Team%22">Institute of Tropical and Infectious Diseases (UNITID) Group and the Kenyan AIDS Vaccine Initiative–Institute of Clinical Research (KAVI-ICR) Team</searchLink> – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%220413675%22">The Journal of infectious diseases</searchLink> [J Infect Dis] 2018 Sep 08; Vol. 218 (8), pp. 1210-1218. – Name: TypePub Label: Publication Type Group: TypPub Data: Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't – Name: Language Label: Language Group: Lang Data: English – Name: TitleSource Label: Journal Info Group: Src Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Oxford+University+Press%22">Oxford University Press </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>0413675 <i>Publication Model: </i>Print <i>Cited Medium: </i>Internet <i>ISSN: </i>1537-6613 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2200221899%22">00221899 </searchLink><i>NLM ISO Abbreviation: </i>J Infect Dis <i>Subsets: </i>MEDLINE – Name: PublisherInfo Label: Imprint Name(s) Group: PubInfo Data: <i>Publication</i>: Jan. 2011- : Oxford : Oxford University Press<br /><i>Original Publication</i>: 1904-2010 : Chicago, IL : University of Chicago Press – Name: SubjectMESH Label: MeSH Terms Group: Su Data: <searchLink fieldCode="MM" term="%22Immunity%2C+Humoral%22">Immunity, Humoral*</searchLink><br /><searchLink fieldCode="MM" term="%22Antibodies%2C+Viral%22">Antibodies, Viral</searchLink>/<searchLink fieldCode="MM" term="%22Antibodies%2C+Viral+metabolism%22">*metabolism</searchLink> <br /><searchLink fieldCode="MM" term="%22Herpesvirus+3%2C+Human%22">Herpesvirus 3, Human</searchLink>/<searchLink fieldCode="MM" term="%22Herpesvirus+3%2C+Human+isolation+%26+purification%22">*isolation & purification</searchLink> <br /><searchLink fieldCode="MM" term="%22Mucous+Membrane%22">Mucous Membrane</searchLink>/<searchLink fieldCode="MM" term="%22Mucous+Membrane+immunology%22">*immunology</searchLink> <br /><searchLink fieldCode="MM" term="%22Vagina%22">Vagina</searchLink>/<searchLink fieldCode="MM" term="%22Vagina+immunology%22">*immunology</searchLink> <br /><searchLink fieldCode="MM" term="%22Varicella+Zoster+Virus+Infection%22">Varicella Zoster Virus Infection</searchLink>/<searchLink fieldCode="MM" term="%22Varicella+Zoster+Virus+Infection+prevention+%26+control%22">*prevention & control</searchLink><br /><searchLink fieldCode="MH" term="%22Antibodies%2C+Viral%22">Antibodies, Viral</searchLink>/<searchLink fieldCode="MH" term="%22Antibodies%2C+Viral+blood%22">blood</searchLink> ; <searchLink fieldCode="MH" term="%22Herpes+Zoster+Vaccine%22">Herpes Zoster Vaccine</searchLink>/<searchLink fieldCode="MH" term="%22Herpes+Zoster+Vaccine+immunology%22">immunology</searchLink> ; <searchLink fieldCode="MH" term="%22Kenya%22">Kenya</searchLink>/<searchLink fieldCode="MH" term="%22Kenya+epidemiology%22">epidemiology</searchLink> ; <searchLink fieldCode="MH" term="%22Varicella+Zoster+Virus+Infection%22">Varicella Zoster Virus Infection</searchLink>/<searchLink fieldCode="MH" term="%22Varicella+Zoster+Virus+Infection+epidemiology%22">epidemiology</searchLink> ; <searchLink fieldCode="MH" term="%22Varicella+Zoster+Virus+Infection%22">Varicella Zoster Virus Infection</searchLink>/<searchLink fieldCode="MH" term="%22Varicella+Zoster+Virus+Infection+immunology%22">immunology</searchLink> ; <searchLink fieldCode="MH" term="%22Female%22">Female</searchLink> ; <searchLink fieldCode="MH" term="%22Humans%22">Humans</searchLink> ; <searchLink fieldCode="MH" term="%22Vaccines%2C+Attenuated%22">Vaccines, Attenuated</searchLink> – Name: Abstract Label: Abstract Group: Ab Data: Background: Attenuated varicella zoster virus (VZV) is a promising vector for recombinant vaccines. Because human immunodeficiencyvirus (HIV) vaccines are believed to require mucosal immunogenicity, we characterized mucosal VZV-specific humoral immunity following VZVOka vaccination.<br />Methods: Adult Kenyan VZV-seropositive women (n = 44) received a single dose of the live zoster VZVOka vaccine. The anamnestic responses to the virus were followed longitudinally in both plasma and mucosal secretions using an in-house glycoprotein enzyme-linked immunosorbent assay and safety and reactogenicity monitored. VZV seroprevalence and baseline responses to the virus were also characterized in our cohorts (n = 288).<br />Results: Besides boosting anti-VZV antibody responses systemically, vaccination also boosted anti-VZV immunity in the cervicovaginal mucosa with a 2.9-fold rise in immunoglobulin G (P &lt; .0001) and 1.6-fold rise in immunoglobulin A (IgA) (P = .004) from the time before immunization and 4 weeks postvaccination. Baseline analysis demonstrated high avidity antibodies at the gastrointestinal and genital mucosa of VZV-seropositive women. Measurement of VZV-specific IgA in saliva is a sensitive tool for detecting prior VZV infection.<br />Conclusions: VZVOka vaccine was safe and immunogenic in VZV-seropositive adult Kenyan women. We provided compelling evidence of VZV ability to induce genital mucosa immunity.<br />Clinical Trials Registration: NCT02514018. – Name: Ref Label: References Group: RefInfo Data: J Infect Dis. 2008 Mar 1;197 Suppl 2:S61-5. (PMID: <searchLink fieldCode="PM" term="%2218419411%22">18419411)</searchLink><br />Vaccine. 2006 Nov 17;24(47-48):6875-85. (PMID: <searchLink fieldCode="PM" term="%2217050042%22">17050042)</searchLink><br />BMJ Open. 2016 Apr 20;6(4):e010213. (PMID: <searchLink fieldCode="PM" term="%2227098823%22">27098823)</searchLink><br />Pediatr Infect Dis J. 2002 Apr;21(4):337-42. (PMID: <searchLink fieldCode="PM" term="%2212075766%22">12075766)</searchLink><br />J Infect Dis. 1998 Nov;178 Suppl 1:S52-4. (PMID: <searchLink fieldCode="PM" term="%229852974%22">9852974)</searchLink><br />Mucosal Immunol. 2018 Mar;11(2):512-522. (PMID: <searchLink fieldCode="PM" term="%2228792003%22">28792003)</searchLink><br />J Clin Virol. 2009 Jan;44(1):9-14. (PMID: <searchLink fieldCode="PM" term="%2218823815%22">18823815)</searchLink><br />Clin Diagn Lab Immunol. 1996 May;3(3):365-7. (PMID: <searchLink fieldCode="PM" term="%228705687%22">8705687)</searchLink><br />Curr Top Microbiol Immunol. 2010;342:189-209. (PMID: <searchLink fieldCode="PM" term="%2220397071%22">20397071)</searchLink><br />J Infect Dis. 2011 Oct 1;204(7):1075-85. (PMID: <searchLink fieldCode="PM" term="%2221881123%22">21881123)</searchLink><br />BMJ Open. 2017 Sep 21;7(9):e017391. (PMID: <searchLink fieldCode="PM" term="%2228939581%22">28939581)</searchLink><br />J Infect Dis. 2008 Mar 15;197(6):825-35. (PMID: <searchLink fieldCode="PM" term="%2218419349%22">18419349)</searchLink><br />N Engl J Med. 2005 Jun 2;352(22):2271-84. (PMID: <searchLink fieldCode="PM" term="%2215930418%22">15930418)</searchLink><br />J Infect Dis. 2014 Nov 15;210(10):1573-81. (PMID: <searchLink fieldCode="PM" term="%2224823623%22">24823623)</searchLink><br />J Clin Invest. 2014 Jul;124(7):3147-58. (PMID: <searchLink fieldCode="PM" term="%2224911151%22">24911151)</searchLink><br />Adv Virol. 2013;2013:219439. (PMID: <searchLink fieldCode="PM" term="%2223843791%22">23843791)</searchLink><br />J Immunol. 2014 Sep 15;193(6):3126-33. (PMID: <searchLink fieldCode="PM" term="%2225143442%22">25143442)</searchLink><br />Lancet. 1974 Nov 30;2(7892):1288-90. (PMID: <searchLink fieldCode="PM" term="%224139526%22">4139526)</searchLink><br />J Infect Dis. 1996 Nov;174 Suppl 3:S314-9. (PMID: <searchLink fieldCode="PM" term="%228896538%22">8896538)</searchLink><br />PLoS Pathog. 2016 Dec 13;12(12):e1006104. (PMID: <searchLink fieldCode="PM" term="%2227959961%22">27959961)</searchLink><br />Trends Immunol. 2014 Nov;35(11):526-37. (PMID: <searchLink fieldCode="PM" term="%2225113637%22">25113637)</searchLink><br />J Med Virol. 2012 Dec;84(12):2018-25. (PMID: <searchLink fieldCode="PM" term="%2223080511%22">23080511)</searchLink><br />JAMA. 2005 Aug 17;294(7):797-802. (PMID: <searchLink fieldCode="PM" term="%2216106004%22">16106004)</searchLink><br />N Engl J Med. 2015 May 28;372(22):2087-96. (PMID: <searchLink fieldCode="PM" term="%2225916341%22">25916341)</searchLink><br />J Clin Lab Anal. 2007;21(3):201-6. (PMID: <searchLink fieldCode="PM" term="%2217506479%22">17506479)</searchLink><br />J Am Osteopath Assoc. 2009 Jun;109(6 Suppl 2):S13-7. (PMID: <searchLink fieldCode="PM" term="%2219553630%22">19553630)</searchLink><br />J Infect Dis. 2011 Feb 1;203(3):312-5. (PMID: <searchLink fieldCode="PM" term="%2221208922%22">21208922)</searchLink><br />J Immunol. 2014 Sep 15;193(6):3113-25. (PMID: <searchLink fieldCode="PM" term="%2225135832%22">25135832)</searchLink><br />N Engl J Med. 2005 Feb 3;352(5):450-8. (PMID: <searchLink fieldCode="PM" term="%2215689583%22">15689583)</searchLink> – Name: GrantInfo Label: Grant Information Group: Grant Data: THA-11960 Canada CIHR – Name: SubjectMinor Label: Contributed Indexing Group: Data: <i>Investigator: </i>J Kimano; J Oyugi; E Irungu; J Nyakio; R Malogo; R Mahira; G Mutua; L Atambo; B Nyaoke; J Nyange; J Omungo; T Kotikot; MW Gichuho; H Ogutu; R Ndambuki; E Museve; HN Gakure; D Essendi; E Mutiska; B Onsembe; M Akiso; S Ogola; N Wanjiku; R Langat; J Indangasi; N Mwakisha; I Mwangi; M Agwaya; R Chirchir; R Alila; L Said; J Wakonyo; M Musanga; C Kamau; M Muriuki; J Ndalamia; C Ngeli; L Lusik – Name: ChemicalData Label: Molecular Sequence Group: ChemData Data: ClinicalTrials.gov NCT02514018 – Name: NumberCAS Label: Substance Nomenclature Group: ID Data: 0 (Antibodies, Viral)<br />0 (Herpes Zoster Vaccine)<br />0 (Vaccines, Attenuated) – Name: DateEntry Label: Entry Date(s) Group: Date Data: <i>Date Created: </i>20180526 <i>Date Completed: </i>20190916 <i>Latest Revision: </i>20190916 – Name: DateUpdate Label: Update Code Group: Date Data: 20260130 – Name: PubmedCentralID Label: PubMed Central ID Group: ID Data: PMC6129112 – Name: DOI Label: DOI Group: ID Data: 10.1093/infdis/jiy320 – Name: AN Label: PMID Group: ID Data: 29800309 |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=cmedm&AN=29800309 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1093/infdis/jiy320 Languages: – Code: eng Text: English PhysicalDescription: Pagination: StartPage: 1210 Subjects: – SubjectFull: Antibodies, Viral blood Type: general – SubjectFull: Herpes Zoster Vaccine immunology Type: general – SubjectFull: Kenya epidemiology Type: general – SubjectFull: Varicella Zoster Virus Infection epidemiology Type: general – SubjectFull: Varicella Zoster Virus Infection immunology Type: general – SubjectFull: Female Type: general – SubjectFull: Humans Type: general – SubjectFull: Vaccines, Attenuated Type: general – SubjectFull: Immunity, Humoral Type: general – SubjectFull: Antibodies, Viral metabolism Type: general – SubjectFull: Herpesvirus 3, Human isolation & purification Type: general – SubjectFull: Mucous Membrane immunology Type: general – SubjectFull: Vagina immunology Type: general – SubjectFull: Varicella Zoster Virus Infection prevention & control Type: general Titles: – TitleFull: Live Attenuated Zoster Vaccine Boosts Varicella Zoster Virus (VZV)-Specific Humoral Responses Systemically and at the Cervicovaginal Mucosa of Kenyan VZV-Seropositive Women. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Perciani CT – PersonEntity: Name: NameFull: Sekhon M – PersonEntity: Name: NameFull: Hundal S – PersonEntity: Name: NameFull: Farah B – PersonEntity: Name: NameFull: Ostrowski MA – PersonEntity: Name: NameFull: Anzala AO – PersonEntity: Name: NameFull: McKinnon LR – PersonEntity: Name: NameFull: Jaoko W – PersonEntity: Name: NameFull: MacDonald KS IsPartOfRelationships: – BibEntity: Dates: – D: 08 M: 09 Text: 2018 Sep 08 Type: published Y: 2018 Identifiers: – Type: issn-electronic Value: 1537-6613 Numbering: – Type: volume Value: 218 – Type: issue Value: 8 Titles: – TitleFull: The Journal of infectious diseases Type: main |
| ResultId | 1 |